glp 1 agonist nash Full article: GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients Frontiers | Future Perspectives on
Description
10.1111/dom.13761 Summary Keywords anti-inflammatory, atherosclerosis, coronary artery disease, glucagon-like peptide-1, mechanisms Citation Skrobucha A, Pindlowski P, Krajewska N, Grabowski M and Jonik S (2024) Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
Frequently Asked Questions What happens if I stop taking Zepbound
Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK
The most commonly reported side effects are those that stem from their action with the digestive system
PubMed Central, Perry, TracyAnn, et al
Trail registration Study registered in clinicaltrials.org with the identifier NCT05535322
